Immatics NV Stock Price

-0.63 (-4.98%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Immatics NV IMTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.63 -4.98% 12.03 00:00:11
Open Price Low Price High Price Close Price Prev Close
12.76 11.99 12.76 12.03 12.66
Bid Price Ask Price Spread News
11.80 19.40 7.60 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,953 154,037 $ 12.28 $ 1,892,144 106,461 8.665 - 19.00
Last Trade Time Type Quantity Stock Price Currency
17:55:58 7 $ 12.00 USD

Immatics NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 756.79M 62.91M 62.91M $ - $ - - -2.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Immatics NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IMTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.9312.9611.1112.00157,5760.100.84%
1 Month14.3715.5911.1112.44240,634-2.34-16.28%
3 Months11.1518.4210.1213.98870,8750.887.89%
6 Months11.5818.429.5813.53462,3530.453.89%
1 Year17.2519.008.66512.86382,553-5.22-30.26%
3 Years17.2519.008.66512.86382,553-5.22-30.26%
5 Years17.2519.008.66512.86382,553-5.22-30.26%

Immatics NV Description

Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.

Your Recent History
Immatics N..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.